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Abstract Introduction In the Netherlands, clopidogrel monotherapy increasingly replaces
acetylsalicylic acid and extended release dipyridamole as the ﬁrst-choice antiplatelet
therapy after ischemic stroke. It is unknown whether the risk of peri- and postoperative
hemorrhage in carotid artery surgery is higher in patients using clopidogrel mono-
therapy compared with acetylsalicylic acid and extended release dipyridamole. We
therefore retrospectively compared occurrence of perioperative major and (clinical
relevant)minor bleedings during and after carotid endarterectomy of two groups using
different types of platelet aggregation inhibition after changing our daily practice
protocol in our center.
Material and Methods A consecutive series of the most recent 80 carotid endarter-
ectomy patients (November 2015–August 2017) treated with the new regime
(clopidogrel monotherapy) were compared with the last 80 (January 2012–Novem-
ber 2015) consecutive patients treated according to the old protocol (acetylsalicylic
acid and dipyridamole). The primary endpoint was any major bleeding during surgery
or in the ﬁrst 24 to 72 hours postoperatively. Secondary outcomes within 30 days after
surgery included minor (re)bleeding postoperative stroke with persistent or transient
neurological deﬁcit, persisting or transient neuropraxia, asymptomatic restenosis or
occlusion, (transient) headache. Reporting of this study is in line with the ‘Strengthen-
ing the Reporting of Observational Studies in Epidemiology’ statement.
Results Although statistical differences were observed, from a clinical perspective
both patients groups were comparable. Postoperative hemorrhage requiring reex-
ploration for hemostasis occurred in none of the 80 patients in the group of the
clopidogrel monotherapy (new protocol) and it occurred in one of the 80 patients (1%)
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The neurological and vascular surgical communities estab-
lished guidelines for antiplatelet therapy as secondary pre-
vention after ischemic stroke or transient ischemic attack
(TIA).1 The American Heart Association guideline states that
the following four antiplatelet regimes are equivalent in the
reduction of the risk of ischemic stroke2:
• Acetylsalicylic acid (ASA)
• Clopidogrel
• Ticlopidine
• Combination of ASA and dipyridamole (ASA-D)
Platelet aggregation inhibition is an essential part of sec-
ondary prevention after TIA or ischemic stroke. International
guidelines approve different antithrombotic regimens for this
induction.2,3 Based on the ESPRIT trial (Level of Evidence 1d
[LoE4]) the initial antiplatelet regime after TIA or ischemic
strokeofpresumedarterial origin consistedofASA80 mgonce
a day and extended release dipyridamole 200 mg twice a day.3
In the PRoFESS (Prevention Regimen for Effectively Avoiding
Second Strokes) trial no differences in cognitive decline or
recurrent stroke were found when comparing ASA 25 mg
tablets in combination with extended release dipyridamole
200 mg (ASA-D) twice a day versus clopidogrel 75 mg once a
day.5
With the PRoFESS trial in mind the antithrombotic treat-
ment protocol in the Medical Center Leeuwarden (MCL) was
changed from ASA-D to clopidogrel monotherapy in Novem-
ber 2015. Contributory reasons for changing this protocol
were the lack of difference in outcome for secondary pre-
vention of a ischemic event between clopidogrel and ASA-D,
an increased incidence of headache in patients after starting
dipyridamole, a potentially higher compliance for monother-
apy, and a cost reduction as clopidogrel monotherapy seems
to be less costly then ASA-D.6,7 Knowledge about the effec-
tiveness, complications, and costs of clopidogrel monother-
apy versus ASA-D may provide insights for other paying
parties, such as health insurance companies and hospitals.
Besides lifestyle changes and medication to prevent recur-
rent TIA or ischemic stroke in the future, patients with a
signiﬁcant and symptomatic carotid artery stenosis require a
carotid endarterectomy (CEA). Although antiplatelet medica-
tion is important as secondary prevention, it also increases the
risk of perioperative hemorrhage.8,9 To date, it is unknown
whether the risk of perioperative hemorrhage is higher in
patients using clopidogrel monotherapy compared with those
using ASA-D when undergoing CEA. ASA and clopidogrel
monotherapy taken 24 hours before CEA increased post- or
perioperative (cervical) bleeding risks.8,10 Knowledge of the
riskofperioperativehemorrhage inclopidogrel versusASA-D is
important because this can cause a potentially life-threatening
situation. In this study, differences in perioperative complica-
tions associated with clopidogrel monotherapy versus ASA-D
were evaluated in patients who underwent CEA for sympto-
matic internal carotid artery stenosis. The ﬁrst aim was to
scientiﬁcally evaluate outcomes of this safety analysis to
provide insight in the complication rate of the operative carotid
population of the MCL. These ﬁrst results on this subject could
be used as step up data for a randomized clinical trial.
Material and Methods
Patients
Between the change in protocol (November 1, 2015) and the
moment of analysis a consecutive series of 80 patients who
were treated with clopidogrel monotherapy (November 1,
2015–August 31, 2017) were compared with the last 80
consecutive patients treated accordingwithASA-D (January 1,
2012–November 1, 2015). Antiplatelet therapy was peri- and
postoperatively continued in both groups. The perioperative
period is deﬁned as the duration between the event (stroke or
TIA) after which the antiplatelet therapy started and the
moment of the CEA. Patient data were retrieved from the
electronic patient ﬁles and were analyzed retrospectively.
Patients were all invited at the outpatient department for
follow up physical examination and carotid ultrasound.
• Inclusion criteria:
– Undergoing unilateral CEA for a symptomatic internal
carotid artery stenosis (> 50% for the male and > 70%
for the female patients).11
– Every patient who underwent a primary CEA in the
period from the January 1, 2012 until August 31, 2017
at the MCL.
• Exclusion criteria:
– Use of vitamin K or factor X-a inhibitors.
– Use of other platelet inhibitor combinations.
– Combination of more surgical interventions at the
same time.
(4%) in the clopidogrel monotherapy and one patient (1%) in the acetylsalicylic acid and
extended release dipyridamole protocol an ipsilateral stroke was diagnosed.
Conclusion In this retrospective consecutive series the incidence of postoperative
ischemic complications and perioperative hemorrhage after carotid endarterectomy
(CEA) seemed to be comparable in patients using clopidogrel monotherapy versus
acetylsalicylic acid and extended release dipyridamole for secondary prevention after a
cerebrovascular event. This study fuels the hypothesis that short- and midterm
complications of clopidogrel and the combination acetylsalicylic acid and extended
release dipyridamole are comparable.
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Preoperative Procedure
As part of standard evaluation all patients with TIA or
ischemic stroke as diagnosed by an experienced vascular
neurologist underwent either computed tomographic angio-
graphy or magnetic resonance angiography of the cerebro-
petal arteries in combination with carotid ultrasonography.
When patients were diagnosed with a symptomatic ipsilat-
eral carotid stenosis ( 50% in male patients and 70% in
female patients) they were referred to the vascular surgeon.
This is according to the Dutch guidelines that also recom-
mends to perform a CEA within 14 days after the initial
ischemic event.11,12 Next to these criteria, when the patient
is scheduled for CEA in our center, the patient is referred to a
dedicated and experienced carotid-team, consisting of a
vascular surgeon, neurologist, anesthetist, vascular internist,
and a specialized nurse for cardiovascular screening.
Surgical Procedure
Surgical procedures were unchanged during the study per-
iod. Conventional CEA was performed under either general
anesthesia or plexus anesthesia.13 Conventional CEA was
performed, as the carotid eversion technique is not used in
MCL given the associated decreased baroreceptor sensitivity
which may be related to difﬁcult postoperative tension
regulation, and because of the damage that can occur from
cutting through the carotid plexus.14,15A 5,000 international
units of heparin were given intravenously during CEA. No
other hemostatic agents were used. A wound drain was not
placed routinely, when placed, it could be removed when it
produced less than 25 mL within 24 hours. The use of a
carotid patch angioplasty is not unequivocally proven.16
However, in the Dutch vascular surgery guidelines it is
recommended.17 At the MCL the use of a carotid patch
angioplasty depends on the diameter of the carotid artery
as can be assessed intraoperatively. All operations were
performed by experienced vascular surgeons, all of whom
hadperformedmore than 200 CEAprocedures. In accordance
with our CEA protocol, all patients were closely monitored
for the ﬁrst 24 hours consisting of vital signs, repeated
neurological tests and wound inspection.18
Endpoints
The primary endpoint was any bleeding (within 30 days after
surgery) requiring hemostasis at the operation room. Sec-
ondary outcomes were death within 30 days after surgery,
minor bleeding, rebleeding, postoperative ipsi- or contral-
ateral stroke, or TIA, cranial nerve neuropraxia, restenosis or
reocclusion, and headache (transient or persisting). Neuro-
praxia symptoms of cranial nerves were diagnosed by an
experienced consultant vascular neurologist.
Endpoints were graded (►Fig. 1) according to importance
for patients according to theGRADEWorkingGroup (Grading
of Recommendations Assessment, Development and Evalua-
tion).19 This study was conducted and reported in line with
the ‘Strengthening the Reporting of Observational Studies in
Epidemiology’ statement (STROBE).20
Statistics
All statistical analyses were performed using SPSS ver-
sion 24.0 (IBM Corp. Armonk, NY). Values were depicted
as mean with standard deviation and number of cases
with percentages. Group differences at baseline were
assessed using Students t-test or Mann–Whitney U-test
for continuous data (depending on normality of data) and
Fisher’s exact test or Pearson’s Chi-square test for catego-
rical data.
Fig. 1 Example of hierarchy of outcomes according to the GRADE classiﬁcation,4,19 adapted for CEA patients.
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Fisher’s exact test was used to test for differences in the
occurrence of primary endpoint events. In addition, the exact
95%conﬁdence intervals (CIs)ofpointestimateswerecalculated
using theClopper–Pearsonmethod. For all secondaryoutcomes,
thesameanalysis approachwasused. Ap-valueof less than0.05
was used for all tests to indicate statistical signiﬁcance.
Results
Between January 2012 and August 2017, a total of 4,514
patients with a stroke or TIA were treated in the MCL. Of
these 4,514 patients 252 underwent CEA in line with the
indications stated in international carotid guidelines. After
exclusion of 92 patients because of predeﬁned criteria, 80
consecutive patients receiving clopidogrel monotherapy
were included. In addition, the most recent 80 consecutive
patients that used ASA-D were included.
Overall, 73% of the 160 CEAwere performedwithin 14 days
after the initial ischemicevent. In caseswhere the timeframeof
treatment was not attained, the reason for this was patient
delay or prehospital referral delay. Patient demographics are
shownin►Table 1 andperioperativeparameters arepresented
in ►Table 2.
Although signiﬁcant differences were found in ►Tables 1
and 2, these differences were considered to be not clinically
relevant.
Although signiﬁcant differences were found in ►Table 2,
these differenceswere considered not to be clinically relevant.
Complications are shown in ►Table 3. Postoperative
hemorrhage requiring return to the operation roomoccurred
in no patients in the clopidogrel monotherapy protocol and
in one (1%) in the ASA-D protocol. Three patients using
clopidogrel and one patient using ASA-D developed an
ipsilateral ischemic stroke. In the 30 day follow-up period
two patients died, both in the clopidogrel group. One patient
died because of a postoperative ipsilateral stroke and one
due to an aspiration pneumonia. The CT-scan (computed
tomography scan) of the patient with the stroke showed no
recent ischemia or bleeding in the brain. There was, in
contrast to a CT prior to the CEA, no signiﬁcant stenosis of
the internal carotid artery. No acute stops or thrombosis in
the artery were seen. The aspiration pneumonia was seen on
X-ray, there was not a CT scan of the brain made ►Table 3.










11 (8–14) 11 (9–14) 0.96
Patch used 39 (49) 70 (88) < 0.001
Dacron 2 (5) 1 (1)
Biopatch 36 (92) 67 (96)
Venous 1 (3) 2 (3)










General 78 (98) 80 (100)
Plexus 2 (2) 0 (0)
Abbreviations: ASA-D, acetylsalicylic acid and extended release
dipyridamole; Biopatch, bovine; IQR, Interquartile Range.
Note: Data are presented as n (%) unless stated otherwise.
Table 1 Patients demographics and surgical parameters, stratiﬁed by antiplatelet therapy regime
Clopidogrel (n ¼ 80) ASA-D (n ¼ 80) p-Value
Period November 2015–August 2017 January 2012–November 2015
Mean age in y (SD) 73 (9.8) 71 (10.8) 0.19
Male 46 (58) 55 (69) 0.19
Comorbiditya 59 (74) 72 (90) 0.01
Hypertension 45 (47) 58 (42)
Diabetes 20 (21) 23 (17)
Hypercholesterolemia 31 (32) 57 (41)
Smoking 53 (66) 49 (61) 0.49
Presenting event 0.87
TIA 36 (45) 38 (47)
Ischemic stroke 44 (55) 42 (53)
Recurrent events between
ﬁrst presentation and CEA
0 (0) 0 (0) NC
Abbreviations: ASA-D, acetylsalicylic acid and extended release dipyridamole; CEA, carotid endarterectomy; NC, not computable; SD, standard
deviation; TIA, transient ischemic attack.
Note: Data are presented as n (%) unless stated otherwise.
aone or more.
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Discussion
In this retrospective analysisnodifferenceswere found inperi-
and postoperative stroke and hemorrhage after CEA between
patients using clopidogrel monotherapy and ASA-D. There
were no differences found in the other deﬁned outcomes in
both groups (clopidogrel monotherapy and ASA-D).
The limitationof this study is its retrospective naturewhich
could imply inaccurately recording of some peri- and post-
operative clinical parameters, e.g., hematoma. Therefore we
interpret the results cautiously. We use these data as step up
study for further research. Also the case-mix, treatment and
outcome are impressible to a certain riskof bias. The incidence
of cervical bleeding/hematomaafter CEA is not easy to observe
reliably and there could have been substantial difference in its
deﬁnition. Nevertheless major bleeding, in need of a reopera-
tion were well documented and therefore considered as an
objective count. Postoperative there are clear symptoms for
the nurse and doctor to check. If there was any suspicion of a
stroke a neurologist was consulted. Therefore the primary
endpoints can be assumed to be well documented.
There is a signiﬁcant difference between the clopidogrel
monotherapy and the ASA-D groups regarding the use of a
patch. Thismaybe trueorcould containa risk for bias. A patch is
useddepending on the diameter of the carotid artery, a variable
that was not reported in all operation reports. Some studies
previously compared the effect of antiplatelet therapy
as secondary prevention after stroke.22–24 Studies speciﬁcally
comparing the effect of antiplatelet therapy prior to and shortly
after CEA are scarce. In the study by Stone et al (2011),
reoperation for bleeding was signiﬁcantly higher in the ASA/
clopidogrel group (1.4%) versus ASA monotherapy (1.2%) or
clopidogrelmonotherapy (0.7%)afterCEA(LoE2b).7 In thestudy
by Weinrich et al (2014), the incidence of revision surgery was
also higher for patients on ASA in combination with any other
antiplatelet drug (commonly clopidogrel)when comparedwith
ASA monotherapy (LoE 2b).25 In both studies the incidence of
postoperative CVA or TIA’s are not mentioned. Other studies
conﬁrmed these ﬁndings.26,27 When comparing ASA-D dual
therapy to triple therapy (dipyridamole, ASA, and clopidogrel)
no signiﬁcantdifferences inpostoperativemicroembolic signals
or bleeding complications were demonstrated.28
Literature suggests the costs of clopidogrel are lower than
ASA-D. The costs of clopidogrel monotherapy in the Nether-
lands vary between €1.18 to 11.83 per patient/per 30 days
depending on themanufacturer (with amaximum of €143.98
annually). The combination ASA-D costs at minimum €15.24
and €16.13 per patient/per 30 days at maximum (and a
maximum of €196.29 annually).29
The results of this study are in line with previously
published literature.30 The changed antiplatelet protocol
did not result in more complications in our consecutive
series. Nevertheless more clinical research may be needed
to conﬁrm or reject these data beforeﬁrm conclusions can be
drawn. It can be hypothesized that clopidogrel monotherapy
could contribute to general therapy compliance and seems to
be more cost effective on annual basis for the CEA patients in
our investigated series. It may be suggested that clopidogrel
should be the preferred choice for CEA patients.
Conclusion
In this retrospective consecutive series the incidence of
postoperative ischemic complications and perioperative
hemorrhage after CEA seemed to be comparable in patients
using clopidogrel monotherapy versus acetylsalicylic acid
and extended release dipyridamole for secondary prevention
after a cerebrovascular event. This study fuels the hypothesis
that short- andmidtermcomplications of clopidogrel and the
combination acetylsalicylic acid and extended release dipyr-
idamole are comparable.
Funding
This researchdidnot receive anyspeciﬁc grant formfunding
agencies in the public, commercial or not-for-proﬁt sectors.
Presentation
This study was presented at the annual meeting of the
Dutch Society of Vascular Surgery (NVvV) on November
2nd 2018.
Table 3 Overview of complications in CEA patients19,21
Clopidogrel (n ¼80) ASA-D (n ¼ 80) p-Value
Cervical hemorrhagea 0 (0) (95% CI 0.0–4.5) 1 (1.2) (95% CI 0.03–6.7) 1.0
Ischemic stroke: ipsilateral 2 (2.5) (95% CI 0.7–8.6) 1 (1.2) (95% CI 0.03–6.7) 1.0
Ischemic stroke: contralateral 0 (0) (95% CI 0.0–4.5) 0 (0) (95% CI 0.0–4.5) NC
Mortality (30 d) 2 (2.5) (95% CI 0.7–8.6) 0 (0) (95% CI 0.0–4.5) 0.50
Neuropraxia of cranial nerves 7 (8.8) (95% CI 3.6–17.2) 9 (11) (95% CI 5.3–20.3) 0.86
Persisting (30 d) 3 (42.8) 4 (44.4)
Transient (< 30 d) 4 (57.2) 5 (55.5)
Headache and/or hypertension 51 (63.8) (95% CI 52.2–74.2) 61 (76.3) (95% CI 65.4–85.1) 0.12
Persisting headache (30 d) 1 (12.5) 0 (0)
Abbreviations: 95%CI, 95% conﬁdence interval; ASA-D, acetylsalicylic acid and extended release dipyridamole; NC, not computable.
Note: Data are presented as n (%) unless stated otherwise.
aRequiring secondary surgery.
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